A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.

Authors

Publication/Presentation Date

1-2019

Volume

37

Issue

4

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Share

COinS